MSMário Cláudio Soares Sturzeneker

Mário Cláudio Soares Sturzeneker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mário Cláudio Soares Sturzeneker has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of the 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension on a Population Sample with a Mean Age of 59 Years

    by Mario Claudio Soares Sturzeneker, Karyn Maria Wenglarek, Jaqueline Meert Parlow, Bruna Karas, Gabriel dos Santos, Fabio de Castro Machado, Ana Beatriz Serrato Carmo, Lorena Grollmann, Laura Moscardi Milléo, Miguel Antonio Schuler Zoni, et al.

    Introduction: Hypertension is a challenge for the global healthcare system due to its high prevalence and importance as a risk factor for the development of cardiovascular disease (CVD) and premature death. Its control remains unsatisfactory, despite the proven efficacy and good tolerance of pharmacological treatment. Clinical practice guidelines are extremely important for guiding the management of these patients. The 2024 European Society of Cardiology (ESC) guideline classified blood pressure (BP) ≥ 120/70 and < 140/90 mmHg as elevated BP, indicating approach, and established a BP < 130/80 mmHg as the therapeutic target. Objective: To evaluate the impact of the 2024 ESC Guidelines (ESC-2024) on blood pressure control rates and the prevalence of individuals requiring approach in a population sample, through a comparative analysis with the 2018 ESC Guidelines (ESC-2018). Methods: This was a cross-sectional study involving adults aged ≥ 18 years. Sociodemographic data, history of cardiometabolic diseases, cardiovascular risk factors, anthropometric data, and BP were collected. The results were expressed as percentages, and comparisons were made using the McNemar test. Results: 504 individuals were evaluated, with a mean age of 59.56 years; 50.59% were men, 40.68% obese, 21.63% diabetic, and 49.21% had a history of hypertension (HH). Under the ESC-2024 criteria, the therapeutic target was reached in 11.70% of hypertensive patients, a percentage 3.48 times lower than that observed when the ESC-2018 criteria were applied (PConclusion: In this population sample, ESC-2024 had a significant impact on hypertension control rates and the prevalence of individuals with indications for approaches, which reinforces the need to adopt evidence-based criteria in our clinical practice and discourages therapeutic inertia.

  • Open Access

    Blockade of the renin-angiotensin system as a therapeutic target of NAFLD: results of an experimental model of hypercholesterolemia

    by M C Soares Sturzeneker, D B Precoma, L De Noronha, P G M Oliveira, F N Viechineski, A M Koscianski, A C Dlugosz, B Karas, C M Calixto, J H Hessman, et al.

    Background/Introduction: Non-alcoholic fatty liver disease (NAFLD) is often associated with metabolic syndrome (MS) and its components, including systemic arterial hypertension (SAH). In a recently published meta-analysis, the estimated prevalence of SAH in patients with NAFLD was 39.34%. Recently published observational studies have shown that the presence of NAFLD is independently associated with an increased risk of identifying SAH. Therefore, we can infer that we will often have to treat SAH in patients with NAFLD and that potential beneficial effects of the antihypertensive drug, in this context, may influence the choice of the respective drug. Purpose: To evaluate the effects of olmesartan in an animal model of NAFLD (hypercholesterolemic rabbits). Methods: 34 rabbits divided into 3 groups: control group (CG) n=13, olmesartan group (OG) n=12 and normal control group (NCG) n=9. The NCG received standard chow for laboratory rabbits, the CG and OG received standard chow plus 1% cholesterol. The OG was medicated with olmesartan 1 mg/kg/day throughout the study period (8 weeks), and the three groups were euthanised in the eighth week. Serum levels of glucose, total cholesterol, triglycerides, creatinine, aspartate aminotransferase (AST) and alanine aminotransferase were evaluated at baseline and euthanasia, and liver tissue samples were taken in the euthanasia from the three groups. Haematoxylin-eosin stained slides were analysed based on the histological scoring system for NAFLD, Gomori,s trichrome stained slides were used for further evaluation of fibrosis, and immunostained slides with antibodies anti-nitric oxide synthase inducible (iNOS) for hepatic oxidative stress analysis. Results: The steatosis (p=0.013), lobular inflammation (p<0.001), ballooning (p=0.039), and fibrosis (p=0.015) scores were significantly lower in the OG compared to the CG. Similarly, NAFLD activity scores were significantly lower in OG compared to CG. The hepatic expression of iNOS was significantly lower in OG than CG (P=0.001). The serum variables results suggest no direct effect of olmesartan in any of them. Conclusion(s): Olmesartan significantly attenuated hepatic oxidative stress, the development of steatosis, lobular inflammation, ballooning, fibrosis and steatohepatitis. Therefore, it suggests that olmesartan may be considered a potentially suitable option for hypertensive patients with NAFLD. Funding Acknowledgement: Type of funding sources: None.

  • Dia mundial da Diabetes: 1ª Edição / World diabetes day: 1st Edition

    by Camilla Mattia Calixto, Bruna Karas, Francielle Nocera Viechineski, Alice Magro Koscianski, Julia Henneberg Hessman, Gilberto Baroni, Gianna Carla Alberti Schrut, Mário Cláudio Soares Sturzeneker

    O diabetes mellitus (DM) afeta cerca de 13 milhões de brasileiros e juntamente com outras doenças crônicas não transmissíveis é a quarta maior causa de mortes no mundo. Os objetivos deste trabalho são esclarecer a população sobre os fatores de risco para DM, esclarecer sobre o potencial deletério dessa doença e promover a saúde incentivando adoção de hábitos de vida saudáveis, aproveitando a alusão ao Dia Mundial do Diabetes. Foram conduzidas anamneses dirigidas, avaliação de medidas antropométricas, aferição de pressão arterial e glicemia capilar. Na sequência, foram realizadas palestras dirigidas à população para disseminar informações de maneira acessível sobre os fatores de risco e formas de prevenção de DM e doenças cardiovasculares (DCV), visto que a presença de DM aumenta em 3 a 4 vezes o risco de DCV devido principalmente a hiperglicemia e a resistência insulínica. As palestras abordaram temas como hábitos de vida mais saudáveis, alimentação e exercício físico. Foram atendidos 36 pacientes, dos quais 55,55% eram homens, 33,35% eram diabéticos confirmados, 35,4% apresentaram glicemia ≥100 mg/dl durante o evento, mas não possuíam diagnóstico de DM e 80% apresentavam sobrepeso ou obesidade. Os fatores de risco mais prevalentes foram a alimentação hiperglicêmica e a história familiar positiva para DM, ambas relatadas por 41,66% dos pacientes. O menos prevalente foi o tabagismo, identificado em 19,44% dos pacientes. Foram feitas orientações caso-a-caso, além de esclarecimento de dúvidas durante o evento.  

  • Dia Mundial da Diabetes 1ª edição / World Diabetes day 1st edition

    by Camilla Mattia Calixto, Bruna Karas, Francielle Nocera Viechineski, Alice Magro Koscianski, Julia Henneberg Hessman, Gilberto Baroni, Gianna Carla Alberti Schrut, Mário Cláudio Soares Sturzeneker

    O diabetes mellitus (DM) afeta cerca de 13 milhões de brasileiros e juntamente com outras doenças crônicas não transmissíveis é a quarta maior causa de mortes no mundo. Os objetivos deste trabalho são esclarecer a população sobre os fatores de risco para DM, esclarecer sobre o potencial deletério dessa doença e promover a saúde incentivando adoção de hábitos de vida saudáveis, aproveitando a alusão ao Dia Mundial do Diabetes. Foram conduzidas anamneses dirigidas, avaliação de medidas antropométricas, aferição de pressão arterial e glicemia capilar. Na sequência, foram realizadas palestras dirigidas à população para disseminar informações de maneira acessível sobre os fatores de risco e formas de prevenção de DM e doenças cardiovasculares (DCV), visto que a presença de DM aumenta em 3 a 4 vezes o risco de DCV devido principalmente a hiperglicemia e a resistência insulínica. As palestras abordaram temas como hábitos de vida mais saudáveis, alimentação e exercício físico. Foram atendidos 36 pacientes, dos quais 55,55% eram homens, 33,35% eram diabéticos confirmados, 35,4% apresentaram glicemia ≥100 mg/dl durante o evento, mas não possuíam diagnóstico de DM e 80% apresentavam sobrepeso ou obesidade. Os fatores de risco mais prevalentes foram a alimentação hiperglicêmica e a história familiar positiva para DM, ambas relatadas por 41,66% dos pacientes. O menos prevalente foi o tabagismo, identificado em 19,44% dos pacientes. Foram feitas orientações caso-a-caso, além de esclarecimento de dúvidas durante o evento.

  • P1870Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits

    by M C Soares Sturzeneker, D Bertolim Precoma, L Noronha, M Olandoski, L Uhlmann Wendling, G E Jacomel, A Gama Palone

    Background/Introduction: Non-alcoholic fatty liver disease (NAFLD) is considered as the most frequent cause of chronic hepatic disease in adults. The renin–angiotensin system has been correlated to the whole basic physiopathogenic mechanism of NAFLD in experimental models. Systemic arterial hypertension has been suggested to be associated with NAFLD in approximately 40% of the cases, and NAFLD has been independently associated with an increased risk of arterial hypertension in observational studies. Therefore, we can infer that treating arterial hypertension in NAFLD carriers will be often necessary and that the potential beneficial effects of the antihypertensive might, in this context, influence the choice of the respective drug.

  • Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia

    by Mário Cláudio Soares Sturzeneker, Sergio Ossamu Ioshii, Liz Andréa Villela Baroncini, Dalton Bertolim Précoma